Volume 7.38 | Oct 1

Mammary Cell News 7.38 October 1, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
 
TOP STORY
Research Connects Specific Variations in RNA Splicing with Breast Cancer Causation
Investigators analyzed the effects of overexpressing a cancer-promoting protein called SRSF1 in both a cellular model of breast cancer and in human breast tumors, and identified changes that could be responsible for SRSF1’s ability to cause cancer. [Press release from Cold Spring Harbor Laboratory discussing online prepublication in Molecular Cell] Press Release | Abstract
Learn More: Standardized Tools for Cancer Research
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

BAP1 Promotes Breast Cancer Cell Proliferation and Metastasis by Deubiquitinating KLF5
Investigators showed that, in breast cancer cells, KLF5 is stabilized by the deubiquitinase (DUB) BAP1. With a genome-wide siRNA library screen of DUBs, they identified BAP1 as a bona fide KLF5 DUB. BAP1 interacts directly with KLF5 and stabilizes KLF5 via deubiquitination. [Nat Commun] Full Article

CPEB1 Mediates Epithelial-to-Mesenchyme Transition and Breast Cancer Metastasis
Researchers showed that cytoplasmic polyadenylation element binding protein 1 (CPEB1)-depleted mammary epithelial cells alter their gene expression profile in a manner consistent with an epithelial-to-mesenchyme transition (EMT) and also become motile, which are made particularly robust when cells are treated with transforming growth factor-β, an enhancer of EMT. [Oncogene] Abstract

LncRNA-Hh Strengthen Cancer Stem Cells Generation in Twist-Positive Breast Cancer via Activation of Hedgehog Signaling Pathway
Investigators discovered that a set of long non-coding RNAs (lncRNAs) were dysregulated in Twist-positive mammosphere cells using lncRNA microarray analysis. The activated hedgehog signaling (Hh) increased GLI1 expression, and enhanced the expression of SOX2 and OCT4 to play a regulatory role in cancer stem cell maintenance. [Stem Cells] Abstract

Mitochondrial Mass, a New Metabolic Biomarker for Stem-Like Cancer Cells: Understanding WNT/FGF-Driven Anabolic Signaling
Researchers developed an isogenic cell model of “stemness” to facilitate protein biomarker discovery in breast cancer. Many of the proteins that were up-regulated by WNT/FGF-signaling in MCF7 cells, were also transcriptionally over-expressed in human breast cancer cells in vivo, based on the bioinformatic analysis of public gene expression datasets of laser-captured patient samples. [Oncotarget] Full Article

Endoplasmic Reticulum Protein 29 (ERp29) Confers Radioresistance through the DNA Repair Gene, O6-Methylguanine DNA-Methyltransferase, in Breast Cancer Cells
The authors reported that ERp29 expression in the triple negative MDA-MB-231 breast cancer cells significantly increased cell survival against ionizing radiation. [Sci Rep] Full Article

DEC1 Regulates Breast Cancer Cell Proliferation by Stabilizing Cyclin E Protein and Delays the Progression of Cell Cycle S Phase
Using the breast cancer cell lines MCF-7 and T47D, scientists showed that DEC1 could inhibit the cell cycle progression of breast cancer cells independently of its transcriptional activity. [Cell Death Dis] Full Article

Antidiabetic Exendin-4 Activates Apoptotic Pathway and Inhibits Growth of Breast Cancer Cells
Exendin-4 is a GLP-1 analog used for the treatment of type 2 diabetes mellitus in its synthetic form. Investigators examined the effect of the incretin drug exendin-4 on breast cancer cells. [Tumor Biol] Abstract

Breast Cancer Cell Line Aggregate Morphology Does Not Predict Invasive Capacity
To further assess the capacity of cell and aggregate morphology to predict invasive capacity in physiologically relevant environments, six cell lines with varied cell aggregate morphologies were assessed in a variety of assays including a 3D multicellular invasion assay that recapitulates cell-cell and cell-environment contacts as they exist in vivo in the context of the primary breast tumor. [PLoS One] Full Article

Modulating Mammary Tumor Growth, Metastasis and Immunosuppression by siRNA-Induced MIF Reduction in Tumor Microenvironment
Researchers developed small interfering RNA (siRNA)-loaded nanoparticle system to effectively reduce migration inhibitory factor (MIF) expression in both breast cancer cells and macrophages. Using this nanoparticle system, they demonstrated that the siRNA-induced MIF reduction in murine mammary cancer line 4T1 and human breast cancer line MDA-MB-231 resulted in significant reduction of cell proliferation and increase of apoptosis. [Cancer Gene Ther] Abstract

CLINICAL RESEARCH

A Phase I Study of a Heterologous Prime-Boost Vaccination Involving a Truncated HER2 Sequence in Patients with HER2-Expressing Breast Cancer
A Phase I clinical trial was conducted to assess the safety, tolerability, and preliminary efficacy of a heterologous prime-boost strategy involving plasmid DNA and an adenoviral vector, in patients with stage III–IV metastatic breast cancer expressing human epidermal growth factor receptor 2 (HER2). [Sci Rep] Full Article

Impact of Prior Anthracycline or Taxane Use on Eribulin Effectiveness as First-Line Treatment for Metastatic Breast Cancer: Results from Two Phase II, Multicenter, Single-Arm Studies
Phase II trials showed clinical activity and acceptable tolerability of first-line eribulin and eribulin plus trastuzumab. [Springerplus] Full Article

See Who's Published: Leading Breast Cancer Researchers Use MammoCult™
 
REVIEWS
Macrophage Migration Inhibitory Factor Involvement in Breast Cancer
Macrophage migration inhibitory factor (MIF) is a pleiotropic inflammatory cytokine involved in many cellular processes and in particular carcinogenesis. The authors reviewed the experimental and clinical published data on MIF and its pathways in breast cancer. [Int J Oncol] Abstract | Download Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
SCIENCE NEWS
Updated Enzalutamide Data in Triple-Negative Breast Cancer Presented at the 2015 European Cancer Congress
Medivation, Inc. announced updated data from a Phase II trial evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced triple-negative breast cancer. [Press release from Medivation, Inc. discussing research presented at the 2015 European Cancer Congress (ECC), Vienna] Press Release

From our sponsor:
Free Cell Stem Cell wallchart – Directed Differentiation of ESCs and iPSCs.
Request your copy.
 
INDUSTRY NEWS
Galena Biopharma Collaborates with the National Cancer Institute on a Phase II Clinical Trial with NeuVax (Nelipepimut-S) in Ductal Carcinoma In Situ Patients
Galena Biopharma, Inc. targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, announced a collaboration with the National Cancer Institute to initiate a new, Phase II clinical trial with NeuVax™ (nelipepimut-S) in patients diagnosed with ductal carcinoma in situ. [Galena Biopharma, Inc.] Press Release

First Human Patient Treated in Phase Ib Study of Advaxis’s ADXS-HER2 in HER2 Expressing Solid Tumors
Advaxis, Inc. announced that the first patient was treated in a Phase Ib dose-escalation clinical study of ADXS-HER2 for the treatment of patients with metastatic HER2 expressing solid tumors. [Advaxis, Inc.] Press Release

Stand Up To Cancer Canada – Canadian Breast Cancer Foundation Dream Team Is Announced
A Stand Up To Cancer Canada Dream Team researching new approaches to treating triple-negative breast cancer and other aggressive types of breast cancer has been formed thanks to a $9 million investment from a coalition of funders. [Canadian Breast Cancer Foundation] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 2nd Matrix Biology Ireland (MBI) 2015
December 2-4, 2015
Dublin, Ireland

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Cancer Biology (The Francis Crick Institute)

NEW Postdoctoral Fellow – Tumor Dormancy (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Scientist – Breast Cancer (Cancer Research UK Beatson Institute)

Postdoctoral Fellow – Breast Cancer Research (University Health Network)

Research Scientist – Epithelial Stem Cells (A*STAR)

Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Fellowship – Cancer Biology (Massachusetts General Hospital Cancer Center/Harvard Medical School)

Postdoctoral Research Fellow – Metastatic Breast Cancer (Fred Hutchinson Cancer Research Center)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us